Analysis of the efficacy and role of Osimertinib (Tagrisso) and actual patient feedback

Osimertinib is a third-generation oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), mainly used to treat EGFR mutation-positive non-small cell lung cancer Cell lung cancer (NSCLC) patients are especially suitable for patients who are resistant to first- or second-generation EGFR-TKI and are accompanied by T790M mutation. Osimertinib irreversibly binds to the mutated tyrosine kinase site of EGFR and simultaneously selectively inhibits the mutant EGFR, but has a weaker inhibitory effect on wild-type EGFR, thereby inhibiting tumor cell proliferation while reducing toxic side effects on normal tissues.

In terms of clinical efficacy, multiple key clinical trials have shown that osimertinib has significant anti-tumor activity. According to the results of the AURA3 study, for NSCLCNSCLCNSCLCwho have failed EGFR-TKI treatment and have the T790M mutation span>For patients, the median progression-free survival (PFS) of the osimertinib treatment group reached 10.1 months, which was significantly improved compared with 4.4 months in the chemotherapy group. The objective response rate (ORR) can reach 71%, indicating that most patients’ tumors are significantly reduced or controlled after treatment. For patients in first-line use, the FLAURA study showed that the median PFS of osimertinib was 18.9 months, compared with The EGFR-TKI group's 10.2 months was significantly prolonged, and the overall survival (OS) was also significantly improved.

Actual feedback from patients shows that osimertinib is well tolerated. Common adverse reactions include rash, diarrhea, stomatitis, dry cough, and mild fatigue. Most are mild to moderate and can be controlled through symptomatic treatment and dose adjustment. A small number of patients may develop cardiacQT interval prolongation or interstitial lung disease (ILD), so electrocardiogram and pulmonary function indicators need to be monitored regularly during long-term use. Many patients have reported that compared with first- or second-generation EGFR-TKIs, osimertinib has significantly reduced gastrointestinal reactions and skin side effects, and improved quality of life, which is particularly important for NSCLC patients undergoing long-term maintenance treatment.

In clinical practice, the use strategy of osimertinib has also been continuously optimized. For NSCLC patients with brain metastasis, osimertinib shows good central nervous system penetration and anti-tumor effect. Brain lesions can be significantly reduced or controlled, thereby improving patients' neurological symptoms and quality of life. In addition, after receiving first-line treatment with osimertinib, some patients can further extend the efficacy through combination chemotherapy or other targeted drugs to achieve personalized treatment. Actual feedback from patients shows that regular medication and regular review of hematology and imaging indicators are the key to ensuring efficacy and safety. At the same time, lifestyle intervention, such as a balanced diet, moderate exercise and psychological adjustment, can also help improve the long-term medication experience.

Overall, osimertinib, as a third-generation EGFR-TKI, has shown significant efficacy and good tolerability in EGFRmutatedNSCLC patients. Both clinical trials and actual usage data show that osimertinib can effectively prolong progression-free survival, improve response rate, and exert special advantages in patients with brain metastases. Patient feedback shows that while controlling tumor progression, the drug has relatively little impact on quality of life, and adverse reactions can be controlled through reasonable management. In the future, with the accumulation of more research and clinical practice, the role of osimertinib in individualized treatment strategies will become clearer, providing more efficient and safer treatment options for patients with EGFRmutated NSCLC.

Reference materials:https://www.drugs.com/